Kura Oncology Amends Executive Agreements; Updates Severance for CEO, CCO, COO

What Happened

• Kura Oncology, Inc. announced amended and restated executive employment agreements with its Chairman/CEO Troy E. Wilson (effective July 24, 2026) and with Chief Commercial Officer Brian Powl and Chief Operating Officer Kathleen Ford (each effective July 27, 2026). The amendments modify certain post‑termination severance and related benefits under those executives’ agreements.
• The agreements set different severance levels depending on timing of a termination relative to a Corporate Transaction (a change‑in‑control type event), including enhanced cash payments, bonus payments, COBRA health premium coverage, accelerated equity vesting in a transaction, and extensions of option exercise periods.

Key Details

• For Troy E. Wilson (CEO):
  • If terminated without Cause or resigns for Good Reason outside the 59‑day pre‑to‑18‑months‑post Corporate Transaction window: cash lump sum = 12 months base salary; COBRA paid up to 12 months; option exercise period extended to the shorter of 12 months and remaining term.
  • If termination/resignation occurs within 59 days prior to, on, or within 18 months after a Corporate Transaction: cash lump sum = 24 months base salary; bonus cash = 200% of target bonus for the transaction year; COBRA paid up to 24 months; full acceleration of outstanding equity awards (performance awards at target); option exercise extension as above.
• For Brian Powl (CCO) and Kathleen Ford (COO):
  • Outside the change‑in‑control window: cash lump sum = 12 months base salary; COBRA paid up to 12 months; option exercise period extended to the shorter of 12 months and remaining term.
  • Within the change‑in‑control window: cash lump sum = 18 months base salary; bonus cash = 150% of target bonus for the transaction year; COBRA paid up to 18 months; full acceleration of outstanding equity awards (performance awards at target); option exercise extension as above.
• The rest of the agreements remain substantially unchanged. Complete copies will be filed with Kura’s Form 10‑Q for the quarter ending September 30, 2026.

Why It Matters

• These amendments increase the executives’ potential post‑termination and change‑in‑control payouts and clarify benefits such as COBRA coverage, equity acceleration, and option exercise windows. For investors, that means Kura has formalized stronger retention and change‑in‑control protections for top management, which can affect the company’s potential cash obligations and the timing/amount of equity vesting (and thus potential dilution) if a Corporate Transaction occurs.
• The filing does not disclose immediate cash expenditures; it documents contingent payments and equity treatment that could become payable under specified termination or transaction scenarios.